Drugs / AZD4017
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01096004 | Mar → May 2010 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00841048 | Feb → May 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00799747 | Dec 2008 → Apr 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00791752 | Nov 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01173471 | Dec 2010 → Nov 2012 | ocular hypertension | AstraZeneca | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03313297 Comparator | Apr 2018 → Feb 2019 | type 2 diabetes mellitus | University of Leeds | Completed | No outcome recorded |
| Phase 2 | NCT03111810 Comparator | May 2017 → Aug 2020 | exogenous Cushing syndrome | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT02017444 Comparator | Apr 2014 → Dec 2016 | pseudotumor cerebri | University of Birmingham | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD4017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01096004 ↗ |
| Known as | CHEMBL2153191 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2153191 ↗ |
| Action | Inhibit | “AZD4017, an inhibitor of 11β-HSD1, will reduce the pressure in the brain” NCT02017444 ↗ |
| Modality | Small molecule | “AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity.” NCT03313297 ↗ |
| Route | Oral | “ascending single doses (start dose 2 mg), oral suspension” NCT00791752 ↗ |
| Target | HSD11B1 | “the orally administered selective 11β-HSD1 inhibitor AZD4017” PMID 37740611 ↗ Oct 2023 |